NCT00135304View on ClinicalTrials.gov

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

PHASE4CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

December 31, 2006

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG

Sensipar®

Cinacalcet hydrochloride

DRUG

Vitamin D

Vitamin D administered IV

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY